Drug profile

The FDA adverse-event record for B12 Injection

22 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference B12 Injection. Species, reactions, and outcomes follow.

#1680 of 2,679
by report volume (all drugs)
22
adverse-event reports
13.6%
death-coded share
Dog
most-reported species
Verify with FDA CVM →

Corpus placement

According to the FDA Center for Veterinary Medicine openFDA adverse-event extract, B12 Injection ranks #1671 of 2679 by total reports (22). Death-coded-share rank requires at least 50 reports. National dual: Milbemycin Oxime + Spinosad is #1 of 2679 drugs by total adverse-event reports (149,624) at death-coded-share rank 965 of 1130 drugs with at least 50 reports (2.3%); separately, Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage) is #1 highest death-coded share at 97.8% (report rank #821).

149,624
Milbemycin Oxime + Spinosad reports (#1)
97.8%
Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage) death share (#1)
#1671
This drug, reports of 2679

Report volume reflects how common a breed or drug is and how often owners and vets file — not actual risk. Death-coded share ranks are limited to entries with enough reports to be meaningful. The two maps do not agree at #1.

Release-over-release change

What changed in the latest FDA data snapshot

PlainBreed reconstructed the prior snapshot from dated openFDA partitions through 2025 Q4, then compared it with the 2026-07-27 openFDA export. B12 Injection has 22 reports now versus 22 in that prior snapshot: 0 the same number of (0.0%).

Report change
+0
Death-coded reports
+0
Death-coded share
−0.0 pts

This compares reported-event counts in two source snapshots. It does not establish a change in real-world risk, product safety, or disease incidence.

Subscribe to B12 Injection changes

Signature read: report volume at 22 is the most distinctive stamp on B12 Injection's FDA AER row.

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
22
Total Reports
3
Deaths Reported
13.6%
Death-coded share of reports

Active Ingredients

B12 Injection

Administration Routes

UnknownSubcutaneousIntravenous

Species Affected

Dog 15
Cat 7

Most Affected Breeds

Domestic Shorthair 3
Terrier (unspecified) 2
Cat (unknown) 2
Poodle (unspecified) 2
Terrier - Yorkshire 1
Siamese 1
Retriever - Golden 1
Crossbred Canine/dog 1
Greyhound 1
Retriever - Labrador 1

Most Reported Reactions

Diarrhoea 7
Behavioural disorder NOS 5
Other abnormal test result NOS 5
Vomiting 5
Ataxia 4
Abnormal radiograph finding 4
Emesis (multiple) 4
Bilirubinuria 4
Monocytosis 4
Heavy breathing 4
Limb weakness 4
Tachycardia 3

Outcome Breakdown

Ongoing
11 (47.8%)
Recovered/Normal
5 (21.7%)
Outcome Unknown
3 (13.0%)
Died
2 (8.7%)
Euthanized
2 (8.7%)

B12 Injection Adverse Event Insights

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

What to do with this drug

A report does not prove a drug caused the reaction; consult a veterinarian before acting on this data.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

openFDA Animal & Veterinary Adverse Events (FDA CVM) for B12 Injection (#1680 of 2,679 by report volume); death-coded 13.6%. PlainBreed drug row · report volume stamp 22 · vintage 2025.

Informational only. FDA adverse-event reports are voluntary and do not prove causation; consult a veterinarian before acting on them. Verify with FDA CVM →